EFFECTOR THERAPEUTICS INC (EFTR)

US28202V2079 - Common Stock

14.39  +0.94 (+6.99%)

After market: 14.39 0 (0%)

Full profile views are only available for registered users, you can see which data is available below.

Examples of complete profiles are available for MSFT and AAPL.

Registered users have access to more data. Please register or login for additional data.

EFFECTOR THERAPEUTICS INC

NASDAQ:EFTR (3/28/2024, 8:06:34 PM)

After market: 14.39 0 (0%)

14.39

+0.94 (+6.99%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)
Earnings (Next)
Ins Owners
Inst Owners
Market Cap44.32M
Shares
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts
IPO
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

EFTR Daily chart

Company Profile

eFFECTOR Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Solana Beach, California and currently employs 15 full-time employees. The company went IPO on 2021-01-08. eFFECTOR Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The firm is focused on the development of oncology drugs, such as selective translation regulator inhibitors (STRIs). The firm uses a selective translation regulation technology platform to internally discover a portfolio of small molecule STRI product candidates. Its product candidates target the eIF4F complex and its activating kinase, MNK. The Company’s lead product candidate, tomivosertib, is an inhibitor of MNK, and is being evaluated in combination with KEYTRUDA (pembrolizumab), an FDA-approved inhibitor of programmed cell death protein 1 (PD-1) in a randomized Phase 2b clinical trial in patients with metastatic non-small cell lung cancer (NSCLC). Its second product candidate, zotatifin, is an inhibitor of eIF4A, a component of the eIF4F complex, and is being evaluated in a Phase 1/2 clinical trial in patients with certain solid tumors. Its third program is focused on developing inhibitors of eIF4E.

Company Info

EFFECTOR THERAPEUTICS INC

142 North Cedros Avenue, Suite B, Suite A

Solana Beach CALIFORNIA

P: 18589258215

CEO: John M. Butler

Employees: 15

Website: https://effector.com/

EFTR News

News Image3 days ago - InvestorPlaceToday’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

It's time to dive into the biggest pre-market stock movers on Tuesday as we check out all of the hottest news moving shares this morning!

News Image3 days ago - InvestorPlaceEFTR Stock Earnings: eFFECTOR Therapeutics Misses EPS for Q4 2023

EFTR stock results show that eFFECTOR Therapeutics missed analyst estimates for earnings per share the fourth quarter of 2023.

News Image3 days ago - BusinessInsiderEFTR Stock Earnings: eFFECTOR Therapeutics Misses EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips eFFECTOR Therapeutics (NASDAQ:EFTR) just reported results for the fourth quarte...

News Image4 days ago - eFFECTOR Therapeutics, Inc.eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
News Image4 days ago - eFFECTOR Therapeutics, Inc.eFFECTOR Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Topline data from the randomized Phase 2b KICKSTART trial of tomivosertib combined with pembrolizumab in non-small cell lung cancer (NSCLC) expected in...

News Image2 months ago - eFFECTOR Therapeutics, Inc.eFFECTOR Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference

EFTR Twits

Here you can normally see the latest stock twits on EFTR, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example